Literature DB >> 16233937

Intranasal immunization of BALB/c mice with enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in biodegradable poly(DL-lactide-co-glycolide) microspheres.

Wyatt Byrd1, Frederick J Cassels.   

Abstract

Mice were intranasally administered enterotoxigenic Escherichia coli colonization factor CS6 encapsulated in poly(DL-lactide-co-glycolide) microspheres (CS6-PLG), with immune response measured and compared to that of similarly administered native CS6 and CS6 plus mutant heat-labile enterotoxin mucosal adjuvant (CS6+mLT). Native CS6 and the CS6-PLG microspheres administered intranasally to mice induced serum IgG responses, with the CS6-PLG microspheres inducing a significantly greater (P<0.001) response than native CS6. Following intranasal administration of native CS6, no fecal IgG and IgA responses were measured; however, the CS6-PLG microspheres induced significantly greater (P<0.001) fecal IgG and IgA responses than native CS6. The coadministration of the mLT mucosal adjuvant with CS6 induced significantly greater serum (P<0.001) and fecal (P<0.01) responses than the CS6-PLG microspheres. However, following intranasal administration of the mLT adjuvant, the mice showed definite signs of distress, indicating an adverse reaction to the mLT. Thus, this brings into question the safety of the mLT and its use as an intranasal adjuvant. In contrast, the PLG-microspheres administered intranasally caused no noticeable distress to the mice. The results obtained in this study indicate that the encapsulation of CS6 in PLG-microspheres administered intranasally to mice acted in an adjuvant capacity to enhance the CS6 immune response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16233937     DOI: 10.1016/j.vaccine.2005.09.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Mucosal and systemic immune responses in patients with diarrhea due to CS6-expressing enterotoxigenic Escherichia coli.

Authors:  Firdausi Qadri; Tanvir Ahmed; Firoz Ahmed; M Saruar Bhuiyan; Mohammad Golam Mostofa; Frederick J Cassels; Anna Helander; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

Review 2.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

3.  Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.

Authors:  Mohammad Murshid Alam; Amena Aktar; Sadia Afrin; Mohammad Arif Rahman; Sarmin Aktar; Taher Uddin; M Arifur Rahman; Deena Al Mahbuba; Fahima Chowdhury; Ashraful Islam Khan; Taufiqur Rahman Bhuiyan; Yasmin Ara Begum; Edward T Ryan; Stephen B Calderwood; Ann-Mari Svennerholm; Firdausi Qadri
Journal:  PLoS Negl Trop Dis       Date:  2014-04-24

4.  Enterotoxigenic Escherichia coli is phagocytosed by macrophages underlying villus-like intestinal epithelial cells: modeling ex vivo innate immune defenses of the human gut.

Authors:  Gaelle Noel; Michele Doucet; James P Nataro; James B Kaper; Nicholas C Zachos; Marcela F Pasetti
Journal:  Gut Microbes       Date:  2017-10-31

5.  Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G.

Authors:  Joyce A Lapa; Stephanie A Sincock; Madhumita Ananthakrishnan; Chad K Porter; Frederick J Cassels; Carl Brinkley; Eric R Hall; John van Hamont; Joseph D Gramling; Colleen M Carpenter; S Baqar; David R Tribble
Journal:  Clin Vaccine Immunol       Date:  2008-06-25

6.  Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.

Authors:  Shu-Chun Chuang; Jing-Chun Ko; Chaio-Ping Chen; Jia-Tze Du; Chung-Da Yang
Journal:  Parasit Vectors       Date:  2013-02-11       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.